LS9 Inc., a startup founded in 2005 to apply synthetic biology technology to production of proprietary biofuels, officially launched today. Synthetic biology is a cross-disciplinary endeavor that designs, optimizes and assembles well-characterized biological components into integrated systems to accomplish specific tasks.
LS9 is developing “Renewable Petroleum” biofuels through work pioneered by scientific founders Chris Somerville, Director of the Carnegie Institution and Professor of Plant Biology at Stanford University, and George Church, Director of the MIT-Harvard DOE GTL Center and Professor of Genetics at Harvard along with venture founders Flagship Ventures and Khosla Ventures.
Somerville is also on Berkeley Labs’s Helios Project advisory committee, and will participate in research projects within Helios areas focusing on synthetic biological approaches and integrated systems.
LS9’s products, currently under development, are designed to closely resemble petroleum-derived fuels, but be renewable, clean, domestically produced, and cost competitive. In addition to biofuels, LS9 will also develop industrial biochemicals for specialty applications.
Thanks to rapid advances in industrial biotechnology and synthetic biology along with the strength and talent of our scientific team, LS9 is uniquely suited to design, develop, and commercialize the next generation of biofuels.—Chris Somerville
Since 2005, the company has pursued a highly focused research and development plan and amassed an extensive technology and intellectual property portfolio for the production of Renewable Petroleum biofuels. Doug Cameron, former head of biotechnology research at Cargill and acting Chief Executive Officer of LS9 Inc., said the advances stand to change the dynamics of the fuel market.
LS9 is pursuing a disruptive technology in a large established market. Our rate of scientific progress is a testament to the quality of the team we have assembled at LS9.—Doug Cameron
The company also relies upon a distinguished scientific advisory board including leaders in the fields of synthetic biology, metabolic engineering, microbiology, enzymology, genomics, bioinformatics, and chemical engineering.